Gilead Sciences, Inc. which can be found using ticker (GILD) have now 25 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $125.00 and $73.00 and has a mean target at $100.96. Now with the previous closing price of $95.59 this is indicating there is a potential upside of 5.6%. Also worth taking note is the 50 day moving average now sits at $91.85 and the 200 day MA is $79.38. The total market capitalization for the company now stands at 120.83B. The stock price is currently at: $96.95 USD
The potential market cap would be $127,609,505,242 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 1077.22, revenue per share of $22.70 and a 11.96% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
